Veliparib plus temozolomide in metastatic melanoma trends toward increased PFS but results are not statistically significant.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000008:administration & dosage; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives; D018572:Disease-Free Survival; D004311:Double-Blind Method; D006801:Humans; D008545:Melanoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000556:secondary*; D009367:Neoplasm Staging; D000077204:Temozolomide
D001562:Benzimidazoles; C521013:veliparib; D003606:Dacarbazine; D000077204:Temozolomide